AstraZeneca (LSE: AZN) is to pull its leukemia antibody-drug conjugate Lumoxiti (moxetumomab pasudotox-tdfk) from the US market later this year.
Poor sales performance of the CD22-directed immunotoxin drug, rather than any issues with safety, has been cited by the Anglo-Swedish pharma major as the reason for the move.
Lumoxiti was approved by the US Food and Drug Administration in 2018 to treat patients with relapsed or refractory hairy cell leukemia who have received at least two prior therapies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze